Evidence map›Paper›PMID 36704104›Full record

ArticleFrontiers in cellular and infection microbiology2022

Jéssica Rebouças-Silva, Gabriel Farias Santos, José Maria Barbosa Filho, Andresa A Berretta, Franciane Marquele-Oliveira, Valéria M Borges

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Jéssica Rebouças-SilvaLaboratory of Inflammation and Biomarkers, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Bahia, Brazil.
Gabriel Farias SantosLaboratory of Inflammation and Biomarkers, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Bahia, Brazil.
José Maria Barbosa FilhoPost-Graduate Program in Natural and Synthetic Bioactive Products, Federal University of Paraíba, João Pessoa, Paraíba, Brazil.
Andresa A BerrettaLaboratory of Research, Development and Innovation, Apis Flora Industrial e Comercial Ltda, Ribeirão Preto, São Paulo, Brazil.
Franciane Marquele-OliveiraLaboratory of Research, Development and Innovation, Eleve Science Research and Development, Ribeirão Preto, São Paulo, Brazil.
Valéria M BorgesLaboratory of Inflammation and Biomarkers, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Bahia, Brazil.
Fundação Oswaldo Cruz · BRApis Flora (Brazil) · BRSUPERA Park of Innovation and Technology of Ribeirão Preto · BRUniversidade Federal da Paraíba · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Yangambin and epi-yangambin are the main lignans found in Louro-de-Cheiro [ Methods: Bone marrow-derived mouse macrophages were infected with Results: Yangambin and epi-yangambin were found to reduce the intracellular viability of either Discussion: The present results serve to encourage the development of novel studies aimed at screening natural bioactive compounds with the hope of discovering new therapeutic options for the treatment of Cutaneous Leishmaniasis.

Indexed as

LeishmaniaLeishmaniasis, CutaneousLignansOcoteaAnimalsFuransMiceMice, Inbred BALB CPlant ExtractsepiyangambinFuransLignansPlant Extractsepi-yangambinLeishmaniaLeishmaniasislignannatural compoundsOcotea fasciculata (Nees) Meztreatmentyangambin

Identifiers

PMID36704104
PMCPMC9872140
OpenAlexW4315433424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.